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OBJECTIVES The study evaluated the relationship between light-to-moderate alcohol consumption and
prognosis in patients with left ventricular (LV) systolic dysfunction.
BACKGROUND Although chronic consumption of large amounts of alcohol can lead to cardiomyopathy, the
effects of light-to-moderate alcohol consumption in patients with LV dysfunction are
unknown.
METHODS The relationship between light-to-moderate alcohol consumption and prognosis was assessed
in participants in the Studies of Left Ventricular Dysfunction (SOLVD), all of whom had
ejection fraction values #0.35. Baseline characteristics and event rates of patients who
consumed 1 to 14 drinks per week (light-to-moderate drinkers, n 5 2,594) were compared
with those of patients who reported no alcohol consumption (nondrinkers, n 5 3,719). The
association between light-to-moderate alcohol consumption and prognosis was evaluated
using Cox proportional hazards analysis, controlling for baseline differences and important
covariates.
RESULTS Mortality rates were lower among light-to-moderate drinkers than among nondrinkers (7.2
vs. 9.4 deaths/100 person-years, p , 0.001). Among patients with ischemic LV dysfunction,
light-to-moderate alcohol consumption was independently associated with a reduced risk of
all-cause mortality (RR [relative risk] 0.85, p 5 0.01), particularly for death from myocardial
infarction (RR 0.55, p , 0.001). The risks of cardiovascular death, death from progressive
heart failure, arrhythmic death, and hospitalization for heart failure were similar for
light-to-moderate drinkers and nondrinkers in this group. Among patients with nonischemic
LV dysfunction, light-to-moderate alcohol consumption had no significant effect on
mortality (RR 0.93, p 5 0.5).
CONCLUSIONS Light-to-moderate alcohol consumption is not associated with an adverse prognosis in
patients with LV systolic dysfunction, and it may reduce the risk of fatal myocardial infarction
in patients with ischemic LV dysfunction. (J Am Coll Cardiol 2000;35:1753–9) © 2000 by
the American College of Cardiology
The consumption of large amounts of alcohol can lead to
the development of cardiomyopathy (1–3). Accordingly, the
consumption of any alcoholic beverages has generally been
discouraged in patients with left ventricular (LV) systolic
dysfunction. However, the relationship between the con-
sumption of alcohol and cardiovascular disease is complex.
Observational studies have consistently demonstrated a
reduction in coronary heart disease risk with light-to-
moderate alcohol consumption (4–7), and coronary heart
disease plays an important role in the development and
progression of heart failure in many patients (8). Further-
more, it is not known whether preexisting LV dysfunction
confers an increased susceptibility to the cardiotoxic effects
of alcohol. We conducted a retrospective analysis of data
from the Studies of Left Ventricular Dysfunction (SOLVD)
Prevention (9) and Treatment (10) trials to assess the
relationship between baseline alcohol consumption and
prognosis in patients with LV dysfunction.
METHODS
The SOLVD Prevention and Treatment trials were ran-
domized controlled studies that evaluated the efficacy of the
angiotensin-converting-enzyme inhibitor enalapril in pa-
tients with LV systolic dysfunction. Patients 21 to 80 years
of age with no history of intolerance to enalapril and an LV
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ejection fraction (EF) #0.35 were eligible for enrollment.
Those with a recent myocardial infarction (MI), significant
valvular heart disease, or other serious comorbid illness were
excluded. Patients with chronic alcoholism were excluded
only if this was deemed likely to interfere with patient
compliance. Patients were required to be clinically stable
and to have had no recent changes in their heart failure
medications. The specific inclusion and exclusion criteria
have been published (9–11). The SOLVD protocols were
approved by the local institutional review board at each
participating center and by the National Heart, Lung, and
Blood Institute. Each participant provided written informed
consent.
Collection of data. All SOLVD participants (n 5 6,797)
underwent a detailed evaluation at entry. Patients were
classified as asymptomatic or symptomatic and then en-
rolled in the Prevention or Treatment trial, respectively.
There were 4,228 patients in the Prevention trial, approxi-
mately one third of whom had New York Heart Association
(NYHA) functional class II symptoms. The Treatment trial
included 2,569 patients, the majority of whom had NYHA
functional class II and III symptoms.
At baseline, participants were asked the average number
of alcoholic drinks they had consumed per week during the
previous two years. Our analyses are based on these self-
reported figures. Data on alcohol consumption were missing
for 91 patients (1.3%), and these patients were excluded
from this analysis. In addition, 97 patients (1.4%) who were
diagnosed with alcoholic cardiomyopathy were excluded
(Fig. 1).
Definition of end points. Follow-up averaged 33.4 6 14.3
months in the two trials combined. Causes of death were
determined by the principal investigator at each clinical site.
Deaths from cardiovascular causes were classified by the
SOLVD investigators as caused by pump failure; probable
arrhythmia with some antecedent worsening of heart failure;
probable arrhythmia with no antecedent worsening of heart
failure; fatal MI; other cardiac, stroke, or vascular cause; or
unknown. In this analysis, all deaths from pump failure and
probable arrhythmia with some antecedent worsening of
heart failure were classified as deaths caused by progressive
heart failure. Arrhythmic deaths were limited to those
classified as probable arrhythmia with no antecedent wors-
ening of heart failure. Two predefined indicators of the
progression of heart failure were death from progressive
heart failure and hospitalization for heart failure. Deaths
from noncardiovascular causes were classified as a cancer or
a noncancer cause.
Baseline variables. Age, blood pressure, and LV EF values
were assessed as continuous variables. All remaining vari-
ables, including study drug allocation (enalapril/placebo),
were assessed as dichotomous variables. The NYHA func-
tional class symptoms were grouped as class I, class II, or
class III/IV. The etiology of LV systolic dysfunction was
classified as ischemic or other (nonischemic) by the enroll-
ing physician. Data on blood lipids were not collected.
Categorization of alcohol consumption. To provide clin-
ically meaningful information, patients were classified as
nondrinkers (average consumption of zero alcoholic drinks
per week), light-to-moderate drinkers (between 1 and 14
drinks per week), and heavy drinkers (more than 14 drinks
per week).
Statistical analysis. Data from the Prevention and Treat-
ment trials were pooled after no interaction was found
between trial assignment and alcohol consumption with
regard to mortality. Evidence of statistical interaction be-
tween alcohol consumption and the etiology of LV dysfunc-
tion was observed (p 5 0.05); thus, ischemic and nonisch-
emic patients were separately evaluated. Continuous
characteristics are presented as mean 6 SD. Pairwise
differences were evaluated using a chi-square test or t-test.
Death from any cause was used as the primary end point in
this analysis, and additional analyses were performed for
Abbreviations and Acronyms
CI 5 confidence interval
EF 5 ejection fraction
HDL 5 high density lipoprotein
LV 5 left ventricular
MI 5 myocardial infarction
NYHA 5 New York Heart Association
RR 5 relative risk
SOLVD 5 Studies of Left Ventricular Dysfunction
Figure 1. Number of alcoholic drinks consumed per week at
baseline for eligible participants in the Studies of Left Ventricular
Dysfunction. (Percentages do not equal 100 because of rounding.)
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cause-specific mortality end points and hospitalization for
heart failure. Incidence rates were calculated as the number
of events per 100 person-years of follow-up.
Multivariate Cox proportional hazards models were used
to assess the independent relationship between alcohol
consumption and mortality. Three multivariate models of
increasing complexity were used in an attempt to highlight
any confounding influences and to minimize the impact of
missing data. The basic model included age, gender, EF,
and NYHA class, adjusting for important demographic and
prognostic factors. As the SOLVD trials were designed to
assess the effect of enalapril, study drug assignment was also
included in this model. An intermediate model added race,
current smoking status, a history of diabetes and a history of
hypertension, as these have also been shown to affect
outcome and were likely to differ between drinkers and
nondrinkers. Finally, a fully adjusted model, which also
included the baseline use of digoxin, diuretics, beta-
blockers, antiarrhythmic drugs, aspirin and anticoagulants,
was used to assess for the possible confounding impact of
baseline medication use. Relative risk (RR) estimates and
95% confidence intervals (CI) were obtained from the Cox
models. Two-sided p values ,0.05 were considered to be
significant. All analyses were performed using Stata: Release
6.0 (College Station, Texas).
RESULTS
Baseline characteristics. The distribution of alcohol con-
sumption at baseline for the 6,609 participants in SOLVD
without alcoholic cardiomyopathy is displayed in Figure 1.
Alcohol consumption ranged from 0 to 84 alcoholic drinks
per week. The majority of participants (55%) were non-
drinkers, while a substantial minority were light-to-
moderate drinkers (38%) consuming 1 to 14 drinks per
week. There were few heavy drinkers (6%) consuming .14
drinks per week. Because the small number of heavy
drinkers precluded accurate risk estimates, this group was
not analyzed further.
Baseline characteristics of nondrinkers and light-to-
moderate drinkers are shown in Table 1. Differences in
mean age, the proportion of women and minorities, NYHA
class, the prevalence of diabetes and hypertension, and
baseline medication use were observed. Mean EF was nearly
identical in the two groups, and a similar proportion of both
groups had ischemic cardiomyopathy. As anticipated, the
proportion of participants who were current smokers was
somewhat higher among light-to-moderate drinkers than
among nondrinkers.
Causes of death. Table 2 shows the causes of death among
nondrinkers and light-to-moderate drinkers. Of the cardio-
vascular causes, progressive heart failure was the most
common cause of death, followed by arrhythmia, MI and
other cardiovascular causes. Light-to-moderate drinkers
had a lower incidence of each cardiovascular cause of death,
except for a slightly higher incidence (not statistically
significant) of deaths classified as other cardiovascular
deaths. Noncardiovascular deaths were also less common
among light-to-moderate drinkers. The incidence of cancer
death was similar in the two groups, while noncardiovascu-
lar deaths from causes other than cancer occurred less
frequently in light-to-moderate drinkers.
Univariate analysis. Before adjustment for baseline differ-
ences, light-to-moderate alcohol consumption, compared
with no alcohol consumption, was associated with a lower
risk of death (RR 0.75, 95% CI 0.68–0.84, p , 0.001).
Other predictors of a lower risk of death among those
patients who were not heavy drinkers included the use of
antiplatelet agents (RR 0.66, 95% CI 0.59–0.73, p ,
0.001), beta-blockers (RR 0.55, 95% CI 0.47–0.65, p ,
0.001) and randomization to the study drug enalapril (RR
0.87, 95% CI 0.78–0.96, p 5 0.006). Predictors of a higher
risk of death included older age (RR per 10-year increase
1.29, 95% CI 1.22–1.36, p , 0.001), nonwhite race (RR
1.57, 95% CI 1.37–1.81, p , 0.001), lower EF (RR per 10%
decrease 1.72, 95% CI 1.59–1.85, p , 0.001), NYHA
functional class III/IV (RR 2.82, 95% CI 2.51–3.17, p ,
0.001), previous hypertension (RR 1.19, 95% CI 1.07–1.32,
p 5 0.001), diabetes (RR 1.59, 95% CI 1.42–1.78, p ,
Table 1. Baseline Characteristics of SOLVD Participants
According to the Level of Alcohol Consumption
Characteristic
0 Drinks/week
(n 5 3,719)
1–14 Drinks/week
(n 5 2,594)
Age (yrs) 61 6 10 59 6 10*
Women (%) 19 9*
Nonwhite race (%) 18 13*
Ejection fraction 27.0 6 6.2 26.9 6 6.3
NYHA class (%)
I 43 47*
II 43 40
III/IV 14 10
Ischemic etiology (%) 80 81
History of diabetes
mellitus (%)
26 12*
History of hypertension
(%)
41 37†
Blood pressure (mm Hg)
Systolic 125.7 6 17.5 124.5 6 16.4†
Diastolic 77.2 6 10.1 77.9 6 9.7†
Current smoker (%) 20 24*
Randomization to
enalapril (%)
50.7 49.6
Baseline use of (%)
Aspirin 45 49†
Beta-blocker 17 19‡
Antiarrhythmic drug 18 18
Diuretic 47 38*
Digoxin 36 31*
Anticoagulant 13 14
NYHA 5 New York Heart Association.
*p , 0.001; †p , 0.01; ‡p , 0.05.
1755JACC Vol. 35, No. 7, 2000 Cooper et al.
June 2000:1753–9 Alcohol and Prognosis in SOLVD
0.001), current smoking (RR 1.18, 95% CI 1.05–1.33, p 5
0.007), and the use of digoxin (RR 2.22, 95% CI 2.00–2.46,
p , 0.001), diuretics (RR 2.45, 95% CI 2.20–2.73, p ,
0.001) and antiarrhythmic drugs (RR 1.40, 95% CI 1.24–
1.58, p , 0.001).
Multivariate analyses. The results for participants with isch-
emic LV dysfunction (n 5 5,331) and nonischemic LV
dysfunction (n 5 1,278) are presented in Table 3 and Table 4.
Ischemic LV dysfunction (Table 3). After adjusting for
baseline differences in age, gender, EF, NYHA func-
tional class and study drug assignment, light-to-moderate
alcohol consumption, compared with no alcohol con-
sumption, was associated with a decreased risk of all-
cause mortality (RR 0.78, 95% CI 0.69 – 0.89, p ,
0.001). This association remained significant when race,
current smoking status, a history of diabetes mellitus, and
a history of hypertension were added (RR 0.82, 95% CI
0.72– 0.93, p 5 0.002). Finally, when the baseline use of
digoxin, diuretics, beta-blockers, antiarrhythmic drugs,
aspirin and anticoagulants were also incorporated, light-
to-moderate alcohol consumption remained significantly
associated with a reduction in the risk of death (RR 0.85,
95% CI 0.75– 0.97, p 5 0.01). The addition of two valid
indicators of socioeconomic status (education level and
presence of economic distress) to the fully adjusted model
did not materially alter the risk estimate for the associa-
tion between light-to-moderate alcohol consumption and
all-cause mortality (RR 0.85, 95% CI 0.74 – 0.98, p 5
0.02). The associations between light-to-moderate alco-
hol consumption and the end points of cardiovascular
mortality and hospitalization for heart failure were sim-
ilar to those for all-cause mortality in each of the three
models (Table 3).
Nonischemic LV dysfunction (Table 4). Light-to-
moderate alcohol consumption, compared with no alco-
hol consumption, was not significantly associated with
the risk of all-cause mortality or cardiovascular mortality
in any of the models. The addition of markers of
socioeconomic status to the models had little effect on the
risk estimates (data not shown). A trend toward an
increased risk of hospitalization for heart failure was
seen in patients with nonischemic cardiomyopathy (p 5
0.1).
Table 2. Causes of Death According to the Level of Alcohol Consumption
Cause of Death
Number of Alcoholic Drinks Consumed per Week
0 (n 5 3,719) 1–14 (n 5 2,594)
No. (%) Incidence* No. (%) Incidence
All causes 963 (25.9) 9.4 531 (20.5) 7.2‡
Cardiovascular 843 (22.7) 8.3 479 (18.5) 6.5‡
Progressive heart failure 397 (10.7) 3.9 225 (8.7) 3.0‡
Arrhythmia 248 (6.7) 2.4 141 (5.4) 1.9‡
Myocardial infarction 140 (3.8) 1.4 58 (2.2) 0.8‡
Other cardiovascular† 58 (1.6) 0.6 55 (2.1) 0.8
Noncardiovascular 120 (3.2) 1.2 52 (2.0) 0.7‡
Cancer 50 (1.3) 0.5 28 (1.1) 0.4
Noncancer 70 (1.9) 0.7 24 (0.9) 0.3‡
*Unadjusted incidence is expressed as the rate per 100 person-years of follow-up. †Includes other cardiac, stroke, or other vascular
or unknown. ‡p , 0.05.
Table 3. Ischemic Left Ventricular Dysfunction (n 5 5,331): Relationship Between Light-to-
Moderate Alcohol Consumption and Outcome
Covariates
All-Cause
Mortality
Cardiovascular
Mortality
Hospitalization
for Heart Failure
Relative Risk (95% CI)
Age, gender, EF, NYHA class,
enalapril
0.78 (0.69–0.89)* 0.82 (0.72–0.93)* 0.78 (0.68–0.91)*
Add: race, smoking, diabetes,
hypertension
0.82 (0.72–0.93)* 0.86 (0.75–0.98)† 0.84 (0.73–0.98)†
Add: digoxin, beta-blockers,
diuretics, antiarrhythmics,
aspirin, anticoagulants
0.85 (0.75–0.97)† 0.90 (0.79–1.03) 0.88 (0.76–1.02)
EF 5 ejection fraction; NYHA 5 New York Heart Association.
*p , 0.01; †p , 0.05.
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Cause-specific mortality end points (Table 5). Because of
the smaller number of cause-specific mortality end points
and the additional missing covariate data in the intermedi-
ate and fully adjusted statistical models, the relationship
between light-to-moderate alcohol consumption and cause-
specific mortality end points was analyzed using only the
basic multivariate model. Among participants with ischemic
LV dysfunction, light-to-moderate alcohol consumption
was associated with a reduced risk of fatal MI (p , 0.001)
and noncardiovascular death (p , 0.01). Among partici-
pants with nonischemic LV dysfunction, light-to-moderate
alcohol consumption was not significantly associated with
any of the cause-specific modes of death, although trends
toward a reduced risk of arrhythmic death (p 5 0.05) and an
increased risk of other cardiovascular death (p 5 0.06) were
observed. Light-to-moderate alcohol consumption was not
associated with an increase in the risk of death from
progressive heart failure in either the ischemic or nonisch-
emic group.
In the SOLVD studies, only 22 deaths (1.5% of all
deaths) were from violent causes. Eighteen patients died as
a result of trauma, and four patients died as a result of
suicide. The proportion of deaths from violent causes was
similar between light-to-moderate drinkers (1.3%) and
nondrinkers (1.5%).
DISCUSSION
To our knowledge, this is the first analysis of the association
between alcohol consumption and prognosis in a large
cohort of patients with preexisting LV systolic dysfunction.
Our data indicate that in patients with ischemic LV
dysfunction, light-to-moderate alcohol consumption (1 to
14 alcoholic drinks/week) was associated with a modest
reduction in the risk of death when compared with no
alcohol consumption. Furthermore, light-to-moderate alco-
hol consumption was associated with a substantially reduced
risk of fatal MI in this cohort. Heart failure progression, as
indicated by either death from progressive heart failure or
hospitalization for heart failure, was not associated with
light-to-moderate alcohol consumption in patients with
ischemic LV dysfunction. Among patients with nonisch-
emic LV dysfunction, light-to-moderate alcohol consump-
tion was not associated with an altered risk of all-cause
mortality or death from any specific cause, including death
from progressive heart failure. However, a trend toward an
increased risk of hospitalization for heart failure was ob-
served in this group.
Alcohol and coronary heart disease. Most observational
studies have demonstrated that light-to-moderate alcohol
consumption is associated with a reduced risk of coronary
heart disease (4–7). Coronary heart disease is the leading
cause of systolic heart failure in the U.S., and it is an
important cause of death and disease progression in this
population (8). Thus, it is plausible that light-to-moderate
alcohol consumption might have beneficial effects in pa-
tients with ischemic LV dysfunction. In SOLVD partici-
pants with ischemic LV dysfunction, light-to-moderate
alcohol consumption was associated with a small but statis-
tically significant reduction in all-cause mortality and a
prominent reduction in the risk of fatal MI. A neutral
association between light-to-moderate alcohol consumption
and mortality was observed in patients with nonischemic
LV dysfunction.
Table 4. Nonischemic Left Ventricular Dysfunction (n 5 1,278): Relationship Between Light-
to-Moderate Alcohol Consumption and Outcome*
Covariates
All-Cause
Mortality
Cardiovascular
Mortality
Hospitalization
for Heart Failure
Relative Risk (95% CI)
Age, gender, EF, NYHA class,
enalapril
0.89 (0.72–1.10) 0.88 (0.70–1.11) 1.13 (0.91–1.40)
Add: race, smoking, diabetes,
hypertension
0.90 (0.73–1.12) 0.89 (0.70–1.12) 1.20 (0.96–1.50)
Add: digoxin, beta-blockers,
diuretics, antiarrhythmics,
aspirin, anticoagulants
0.93 (0.74–1.16) 0.92 (0.72–1.18) 1.21 (0.97–1.52)
EF 5 ejection fraction; NYHA 5 New York Heart Association.
*p $ 0.1 for all comparisons.
Table 5. Relationship Between Light-to-Moderate Alcohol
Consumption and Cause-Specific Mortality*
Cause of Death
Ischemic LV
Dysfunction
(n 5 5,331)
Nonischemic
LV Dysfunction
(n 5 1,278)
Relative Risk (95% CI)
Progressive heart
failure
0.86 (0.71–1.05) 0.89 (0.66–1.20)
Arrhythmia 0.84 (0.67–1.06) 0.62 (0.38–1.00)
Fatal myocardial
infarction
0.55 (0.40–0.76)† 1.07 (0.46–2.50)
Other cardiovascular 1.28 (0.82–2.00) 2.06 (0.98–4.33)
Noncardiovascular 0.54 (0.37–0.81)† 0.97 (0.52–1.80)
*Other covariates included in the model were age, sex, ejection fraction, NYHA class,
and randomization to enalapril. †p , 0.05.
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Alcohol and LV performance. Previous research has dem-
onstrated that heavy alcohol consumption is related to the
development of cardiomyopathy. In animal models, chronic
alcohol consumption leads to interstitial fibrosis and re-
duced myocardial contractility (1,12). In humans, chronic
alcoholism is associated with a high prevalence of subclinical
LV systolic dysfunction and histologic changes of cardio-
myopathy (2). Despite this, there is no experimental evi-
dence that light-to-moderate alcohol has a deleterious effect
on LV performance. Indeed, invasive hemodynamic studies
have generally demonstrated either no acute effect or a
transient increase in LV contractility after the administra-
tion of a moderate amount of alcohol to patients with LV
systolic dysfunction (13,14) or hypertrophic cardiomyopa-
thy (15), or to normal volunteers (16,17). In the current
analysis, no association between light-to-moderate alcohol
consumption and the risk of heart failure progression (death
from progressive heart failure or hospitalization for heart
failure) was present in patients with ischemic LV dysfunc-
tion. Among those with nonischemic LV dysfunction,
although a modest trend toward an increased risk of
hospitalization for heart failure was seen, there was no
increase in the risk of death from progressive heart failure.
Taken together, these results suggest that light-to-moderate
alcohol consumption does not significantly worsen preexist-
ing LV dysfunction over the intermediate term.
Comparison to previous studies. Our results agree closely
with previous research. In a substudy of the Physicians’
Health Study, which examined the relationship between
alcohol consumption and mortality in men following a first
MI, consumption of one drink per day was associated with
a RR reduction of 21% for all-cause mortality and 17% for
cardiovascular mortality (18). These figures are similar to
the RR reductions of 15% and 10% found in the current
analysis for light-to-moderate drinkers with ischemic LV
dysfunction.
Light-to-moderate alcohol consumption was associated
with a prominent (45%) reduction in the risk of fatal MI in
SOLVD participants with ischemic LV dysfunction. This
reduction is similar in magnitude to that observed in the
complete Physicians’ Health Study cohort, in which con-
sumption of one drink per day was associated with a 35%
RR reduction for a first MI (7). A case control study of a
cohort of Kaiser Permanente patients found a RR reduction
of 30% for MI in those who consumed #2 drinks daily
when compared with nondrinkers. A smaller but still
statistically significant risk reduction was seen even in the
category of patients who consumed alcohol only infre-
quently (.1 drink per month but ,1 drink per day) (19).
The lack of association between light-to-moderate alcohol
consumption and fatal myocardial infarction among
SOLVD participants with nonischemic LV dysfunction is
not surprising considering the rarity of this event.
Heavy alcohol consumption has been linked to cardiac
arrhythmias, particularly atrial fibrillation but also ventric-
ular arrhythmias (1,20). However, in our analysis, light-to-
moderate alcohol consumption was associated with trends
toward reductions in the risk of arrhythmic death among
patients with either ischemic LV dysfunction or nonisch-
emic LV dysfunction. These findings agree closely with
previous studies. In the Kaiser Permanente study cohort, a
comparable level of alcohol consumption was associated
with a 20% reduction in the risk of sudden cardiac death
(21), and in a population-based study from Washington
State, the risk for primary cardiac arrest was 30% lower in
light drinkers (.1 drink per month and ,1 drink per day)
compared with nondrinkers (22).
In the present analysis, light-to-moderate alcohol con-
sumption was associated with a prominent reduction in the
risk of noncardiovascular death among SOLVD participants
with ischemic LV dysfunction. However, because the num-
ber of noncardiovascular deaths were few, these results
should be interpreted with caution. Nonetheless, our find-
ings are similar to those from the cohort of patients in the
Physicians’ Health Study following a first MI, in whom one
drink per day was associated with a 34% relative reduction in
the risk of noncardiovascular death (18). Other studies have
described a similar relationship (19,23,24). It has been
postulated that noncardiovascular mortality may be lower
because cardiovascular comorbidity is reduced in light-to-
moderate drinkers (23,24). Further research is required to
clarify this issue.
Study limitations. Our analysis has several limitations.
First, the relationship between alcohol consumption and
prognosis may have been confounded by factors other than
those for which we adjusted. This issue might be of
particular importance in the analyses of cause-specific mor-
tality end points, for which only the basic model was used.
However, the detailed characterization of the SOLVD
cohort, the small changes in risk estimates despite increas-
ingly comprehensive statistical models, and the close agree-
ment between our results and previous research make this
less likely.
Second, our analyses are based on participants’ self-
reported alcohol consumption. Although self-reported
mild-to-moderate alcohol consumption is generally reliable,
heavy drinkers tend to underreport their alcohol use (25).
We attempted to minimize the effect of this possible
underreporting by excluding participants with alcoholic
cardiomyopathy; but even if a substantial number of heavy
drinkers were incorrectly included with the light-to-
moderate drinkers, our results would overestimate, rather
than underestimate, any harmful effect of alcohol consump-
tion.
Third, patients may have altered their drinking habits
after entering the trial, an occurrence for which we could not
adjust. Fourth, research in other patient populations has
demonstrated that approximately 50% of the benefit of
alcohol consumption with regard to coronary heart disease is
brought about by its effects on high density lipoprotein
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(HDL) cholesterol levels (4). Because blood lipid values
were not collected in the SOLVD trials, we were unable to
analyze this relationship. Finally, the average duration of
follow-up in SOLVD was only about three years. There-
fore, we lack information on the long-term effects of alcohol
consumption in this population.
Conclusions. Light-to-moderate alcohol consumption ap-
pears to be safe in patients with LV systolic dysfunction, and
it may reduce the risk of death and the risk of fatal MI in
patients with ischemic LV dysfunction. Patients with LV
dysfunction who consume #2 drinks per day should not be
advised to discontinue drinking alcohol for the purpose of
reducing cardiovascular morbidity or mortality. However,
there is insufficient evidence to recommend the use of
alcohol to patients with LV dysfunction who do not
currently drink alcohol. Heavy alcohol consumption should
continue to be discouraged for patients with LV systolic
dysfunction, because of the clear increase in noncardiovas-
cular and total mortality shown in previous studies
(19,23,24) and because of the strong evidence that heavy
alcohol consumption can lead to impairment of LV con-
tractile function (1,2,12).
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